We would love to hear your thoughts about our site and services, please take our survey here.
See volume and price have perked up on Nasdaq..... History tells me that this price action is a pre-curser to news... picked up quite a few more today. Perhaps this is the time the signal is false.... still reading the latest update and listening to the webcast (more useful... re tone of delivery) I agree with other posters that the SP does not reflect a sum of the parts valuation. Interesting times...
I agree George-Inn with your sentiments. From my perspective timing is the one thing that makes me wonder here. Could it be that Jim has found a position elsewhere having proposed a reduction in board costs in the last funding round ( I assume it has been enacted ).... Or Jim's view of the direction of travel with the business does not align with other stakeholders. Why not report this in a couple of weeks in April with the promised update... ? Still the US price went up on the Nasdaq and some chunky trades of late. Also our major holder Woodford appears to be rebalancing his portfolio in light of his own challenges. So all in all I hope for 'dramatic' developments and some positive sentiment. There was a research paper written (think it was Capital Network) only a couple of days ago, so MTPH should be on the radar of many..... roll on the April update.
Hmmm.... imo a good update today. Looks like MTPH is cranking up the schedule on MTD119 now up to half of the clinical trials cost, a tax exemption and a corporate tax rebate is available (source .. a google of Orphan Drug financial aid). Seem to recall that in the late 2017 webcast Jim advised they were looking for a partner for full trial cover. So imo a shot in the arm for MTPH and MTD119 has moved up on the rails re the 'value inflection point' announcement late this year... Just the toxicology hurdle to overcome.... reporting this half so all in all looking half good here.
No surprises. April will flush out the detail and confirm 'value inflection point' timing. Should have an update on US pickup Qtr 1 and other detail, including the management contribution to cost reduction. No reason to change my thoughts on the outcome. Roll on April.
Thats four ticks out of four in my book. Should at least highlight Midatech to a wider investment audience. Just need the US business to deliver as noted by Jim in the up and coming results then we should see a timely uplft in the SP.
I agree George-Inn. So eyes down for a pivotal RNS mid year. If what Midatech have announced to date on the pre trial results for this offering are as reported then we should be in for a bit of a spike up on the RNS reporting commercial scale up. This is a binary bet and my money is on Jim coming good. Still holding and await the promised US turn around in the next results update.
Spotted this this after the close today and thought others would find useful. http://www.proactiveinvestors.co.uk/companies/news/189466/shares-in-midatech-pharma-up-50-after-drug-developer-ties-up-non-dilutive-funding-deal-189466.html
Two down, two to go. If we get the thumbs up on both in the coming weeks then we can look forward to significant uplift in the SP. See that MTP on the Nasdaq is up 150% as I type this..... Well done for those who kept buying to mid 30's.
Was expecting news by now. Jim advised on the teleconf for the last results that he had 'paper in' from lenders for finance north of £15 Mil which must have been end Sept early Oct. The company has no debt and NAV of circa 75p according to ADFN. A market cap of £25 Mil and lots of potential. I suppose that things are tight (pay drop for Directors) as are RNS's so they are packaging up updates into one RNS.... or summit else is going on. Interesting times.
We were guided to expect news on 4 fronts between now and year end. Perhaps we are closer to another RNS now the upscale in production has been certified, Q-Octreotide, DIPG, Gelclair expansion study and not forgetting the debt deal with an institution. Guessing on the next couple of weeks unless there is another spanner about to materialise. Still holding and hoping....
Just had a listed to Jim et al re the Interim's. Very informative 'n all, suspect the catalyst for the slide was the upscaling of Bilbao and the problems and cost and indeed time (which is money) this caused. Good to hear all sorted now but this I reckon what mainly upset the applecart here. In addition the US team and need to refocus and reduce headcount just compounded the cash position and I suspect when the enquires (for funds) was made then this was a reason for the move in the SP from 100p south. Jim reports he has term sheets from bidding banks now the good old shareholders have had to copper up ( well Woodford and L&G ) and it appears Midatech subject to debt agreement are funded up to the release of results 2018 on pivotal programs. Interested that post Phase 1B the Liver Cancer treatment will seek a partner (sensible in my eyes). Also Jim reported lots of interest from other parties all waiting for the readout from the studies in 2018. Next news late Nov I reckon on one or two studies being started, quickly followed by debt facility. I am remaining invested (and underwater) awaiting a reversal in fortunes 2nd half 2018. No more shares for me though.... good luck all. GDT
Posted yesterday. Reckon next news will be debt facility back end 2017. Imagine this one will be a close call and 2018 is the year that Midatech will rise beyond my average (I wish) or otherwise. Wonder what the salary cut will be I will plump for 40%...
Reading the update there was a presentation and recording promised. I assumed they would be posted on the web site. Not a sausage so far so suspect I have missed it. One thing that I did find interesting in the placing RNS was the following "The Board is committed to continuing to reduce costs across the business, including an immediate substantial reduction in senior management compensation until there has been a significant recovery in the Company's share price. Further, a reduction in the costs and, in due course, the size of the Board itself, is being undertaken, such that the total Board costs on an annualised basis will be significantly lower to that of last year."...wonder what substantial and significant are .. still shows genuine commitment from Mgt.
Hmmm.... I did not see that one coming.... unlike others.... Someone on the company financial side seems to me to have dropped a ball here re contingency and financial planning given the cash raise in 2016. Still I have heart in the products and core scientific know how & expertise.... just frustrated as most I am sure. More reason in my mind that other companies will be circling as the three lead products have very good potential imo. Nothing more to say other than this is destined for the bottom draw awaiting a reversal of fortunes... the only positive I can draw from the updates this AM is that I can wait and 2018 should provide some news that will crystalise our faith be it proven or otherwise...
Very interesting presentation and commentary. See that the US is in profit (last couple of months). More importantly lots of traction on three main programs. I was listening hard for negatives / problems but nothing seemed to arise. Looks like 2018 will be pivotal for news flow on all the major programs with the add on for the Gelclair derivative which adds revenue. To be honest was very happy with all I heard from Jim. Will the SP reflect this.... eventually I am sure.... just when we reach eventually is what I can not put my finger on. OT but some strange trades of late ... the trade of 1 share some say is a signal... time will tell but all things considered I have no reason to reduce my holding.
Just seen the note on the 21st Sept Edinburgh presentation by Jim, that is quite a few meet and greet sessions of late what with New York on the 11th and one in August. My take on this raft of presentations is Jim has a good story to tell but can see the SP drifting (I hope for no good reason other than more sells than buys) the volumes have also been pretty low given the free float. Will be keeping an eye on the presentation packs as they are released with commentary if available. Happy to hold and await news..... not long now...
See that the 28th is now pencilled in for the Interims. As to the reason for the delay I can only ponder. Still a webcast will be available for the presentation on the 11th in New York by Jim. So eyes (and ears) down for the 12th so see if we get any useful snippets. Given the results reference the past then what I wonder the reason for plumping the 28th ?... I'm intrigued.
Reckon the weakness is around the pending update for the Production facility at Bilbao. Looking at the volumes and delayed trades I think it is a case of the MM's grabbing shares on the cheap. Just took a few more myself. Though you never know it might be something else that has caused the drop. If the SP drops a lot I will just let the kids know their inheritance is a little smaller. Lets see what September brings as I will now wait for the update from Jim.
Evening, looks to me that this is a shuffling of deckchairs. If you look at existing holders you will see Ferracom has exactly the same number of shares......so I am assuming a title (name) change.... both have links to Liechtenstein.
Had a good root around and I can see no adverse news affecting Midatech, perhaps as you say bad news or leak. I had intended to top up if it breached 100p and the results had no surprises. We have more sells than buys but there may be a delayed trade or two in the works. I will wait until mid next week and if there is no news or reported delayed sells then I will be buying a few more, saving some for the Interim's in September. So..... given it is AIM and swings in the SP tend to be higher than the main market I reckon on balance we have a few investors who are selling as the £1 barrier has broke and others adding to shorts ...... but to be honest like all investors in AIM I dunno.... so sticking to my maxim "When in doubt to nowt", I will wait for the dust to settle and see what next week brings.